Patent · US Active

Use of survivin antagonists in polyomavirus-related disease

US9662329B2 · kind B2 · utility

3Cited by

1References

15Claims

0Family size

Assignee

University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

Yuan Chang · New York, US
Patrick S. Moore · New York, US

Key dates

Filing date	Mar 26, 2013
Grant date	May 30, 2017
Priority date	—
Expiry date	Jul 9, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating a polyomavirus (+) cancer in which survivin is upregulated in a patient is provided, comprising administering to the patient a therapeutically effective amount of a composition that downregulates survivin expression or function in cells of the polyomavirus (+) cancer. A method of reducing growth of polyomavirus (+) cancer cells in which survivin is up-regulated is provided, comprising contacting the cells with an amount of a composition that downregulates survivin expression or function effective to reduce growth of the cells. Also provided is sepantronium salt, for use in treating a polyomavirus (+) cancer in which survivin is up-regulated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.